有効性試験の市場：サービスタイプ（抗菌・防腐剤有効性試験、殺菌剤有効性試験）、用途（医薬品、化粧品・パーソナルケア、医療機器、消費者製品）、地域別 - 2027年までの世界予測

Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027

効能試験の世界市場は、2022年の3億1500万米ドルから2027年には4億2300万米ドルに達すると予測され、予測期間中のCAGRは6.1%となります。この市場の成長は、主に製薬、バイオ医薬品、化粧品業界において、汚染防... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年7月19日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	176	179	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

効能試験の世界市場は、2022年の3億1500万米ドルから2027年には4億2300万米ドルに達すると予測され、予測期間中のCAGRは6.1%となります。この市場の成長は、主に製薬、バイオ医薬品、化粧品業界において、汚染防止と製品安定性のために表面殺菌剤と防腐剤の使用が増加していること、有効性試験のアウトソーシングを好む傾向が高まっていること、QbDアプローチの採用が増加していることに起因しています。新興市場の高い成長性は、有効性試験市場で活動するプレーヤーに成長機会を提供します。
"試験法の種類別では、従来の試験法が抗菌・防腐剤試験市場で最大のシェアを占めている"
従来の試験法は一般的に、長期間にわたる複数の試験点での微生物アッセイを必要とします。試験期間は、最低28日間から12週間以上に及ぶのが一般的です。より長期の一般的なチャレンジプロトコルで採用されているのと同様の標準的な微生物学的技術が関与しているため、アッセイを実施するために特別な設備やトレーニングは必要ありません。実際、この加速二重チャレンジ（ADC）アッセイは、現在、多くの研究所で様々な用途に基本形またはバリエーションで使用されています。
"予測期間中、医薬品製造アプリケーションのセグメントが最も高い成長率を示すだろう"
有効性試験市場は、用途別に、医薬品製造用途、化粧品・パーソナルケア製品用途、消費者製品用途、医療機器用途に区分されます。2021年には、医薬品製造用途が市場最大の製品セグメントとなりました。この市場の成長は、大手製薬会社による研究開発製造の増加、政府の支援、製薬業界の成長、患者の安全性への注目の高まりに起因すると考えられます。
"アジア太平洋地域の市場は、予測期間（2020-2027年）において最も高い成長率を示すと予測されます。"
アジア太平洋地域の市場は、予測期間中に最も高いCAGRで成長すると予測されています。これは主に、医療に対する政府支出の増加、老人人口の増加、消費者の健康意識の高まり、慢性疾患の発生率の増加によりこの地域の医薬品の成長の原因となっていること、APAC諸国で製造施設を設立する製薬会社の数が増加していることに起因しています。
「北米：効能試験市場の最大シェア
北米は効能試験市場の最大シェアを占めている。この地域には確立された製薬業界が存在すること、研究開発費が高いこと、大手サービスプロバイダーの存在感が強いこと、この地域の製薬会社や化粧品会社による分析試験（有効性試験を含む）のアウトソーシングが増加していることなどが、市場成長の主要因である。

プライマリーの内訳

本調査には、部品サプライヤーからティア1企業、OEMに至るまで、様々な業界専門家による洞察が含まれています。プライマリーの内訳は以下の通りです。

- 回答者別：供給側80％、需要側20
- 役職別：役員25％、CXO20％、管理職55
- 地域別：北米50％、欧州20％、APAC20％、RoW 10

有効性試験市場で事業を展開する主要企業は、Charles River Laboratories（米国）、WuXi AppTec（中国）、Eurofins Scientific（ルクセンブルク）、SGS（スイス）、Intertek Group（英国）、Nelson Laboratories, LLC（a Sotera Health company、米国）、Microbac Laboratories, Inc.（米国）、Almac Group（英国）、North American Science Associates, Inc.（英国）となっています。(米国）、Toxikon（米国）、Pacific Biolabs（米国）、MSL Solution Providers（英国）、Intertek Group PLC（英国）、Accugen Laboratories, Inc.（米国）、 Consumer Product Testing Company（米国）、Lucideon（英国）、 BioScience Laboratories, Inc（米国）、ALS Limited（オーストラリア）、 Microchem Laboratory（米国）、 Oxford Biosciences Ltd. (米国), Inc.(英国）、Abbott Analytical（オーストラリア）、Helvic Laboratories（a Tentamus Company、英国）、Honeyman Group Limited（英国）、Danish Technological Institute（DTI、デンマーク）、BluTest Laboratories Limited（英国）などがあります。

調査対象

本レポートでは、地域（アジア太平洋、欧州、北米、RoW）、サービスタイプ（殺菌効力試験、抗菌・防腐効力試験）、用途（医薬品製造用途、化粧品・パーソナルケア製品用途、消費財用途、医療機器用途）に基づき効力試験市場をセグメントしています。

また、効能試験市場における市場促進要因、課題、機会に関する包括的なレビューも提供しています
レポート購入の主なメリット

本レポートは、市場全体とサブセグメントに関する収益数の最も近い近似値に関する情報を提供し、この市場のリーダー/新規参入者を支援します。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、利害関係者が効能試験市場の鼓動を理解するのに役立ち、主要な市場促進要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。
- 市場の浸透度。効能試験市場におけるトッププレイヤーの製品ポートフォリオに関する包括的な情報。本レポートでは、サービスタイプ、アプリケーション、地域に基づいて市場を分析しています。
- サービスの開発/革新。有効性試験市場における今後の技術、研究開発活動、サービス/製品の発売に関する詳細な洞察。
- 市場開発。有利な新興市場に関する包括的な情報。本レポートでは、地域ごとに様々なタイプの効能試験ソリューションの市場を分析しています。
- 市場の多様化。有効性試験市場における製品/サービス、未開拓地域、最近の開発、投資に関する詳細な情報を提供します。
- 競争力の評価。有効性試験市場における主要企業の市場シェア、戦略、製品、流通網、製造能力に関する詳細な評価を行います。

ページTOPに戻る

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 YEARS CONSIDERED 26
1.4 CURRENCY 26
1.5 LIMITATIONS 26
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
2.1.1 SECONDARY DATA 28
2.1.2 PRIMARY DATA 28
2.1.2.1 Breakdown of primary sources 29
FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29
2.1.2.2 Key industry insights 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 30
FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS 31
FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 32
FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
2.4 MARKET RANKING ANALYSIS 35
2.5 RESEARCH ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE,
2022 VS. 2027 (USD MILLION) 36
FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 37
FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET 37

4 PREMIUM INSIGHTS 39
4.1 EFFICACY TESTING MARKET OVERVIEW 39
FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH 39
4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021) 40
FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 40
4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET 41
FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027 41
4.4 EFFICACY TESTING MARKET, BY REGION 41
FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027 41
4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 42
FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability 44
5.2.1.1.1 Growing focus on contamination control 44
5.2.1.1.2 Increasing concerns over product stability 44
5.2.1.2 Growing preference for outsourcing efficacy testing 44
5.2.1.3 Rising adoption of quality by design approach 45
5.2.1.4 Stringent regulations for use of surface disinfectants 45
5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19 46
5.2.2 RESTRAINTS 46
5.2.2.1 Adverse effects of chemical disinfectants 46
5.2.3 OPPORTUNITIES 47
5.2.3.1 Emerging countries in Asia Pacific 47
5.2.4 CHALLENGES 47
5.2.4.1 Time-consuming process 47
5.3 REGULATORY ANALYSIS 47
5.3.1 DISINFECTANT EFFICACY TESTING 48
5.3.2 ANTIMICROBIAL EFFICACY TESTING 48
5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES 49
5.5 PRICING ANALYSIS 49
TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022) 49
5.6 PATENT ANALYSIS 51
5.7 TRADE ANALYSIS 51
5.7.1 TRADE ANALYSIS FOR DISINFECTANTS 51
TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 51
TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 52
5.8 VALUE CHAIN ANALYSIS 52
FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET 52
5.9 ECOSYSTEM ANALYSIS 53
FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS 53
TABLE 4 ROLE IN ECOSYSTEM 54
5.10 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 5 EFFICACY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.10.1 THREAT OF NEW ENTRANTS 55
5.10.2 THREAT OF SUBSTITUTES 55
5.10.3 BARGAINING POWER OF BUYERS 55
5.10.4 BARGAINING POWER OF SUPPLIERS 55
5.10.5 DEGREE OF COMPETITION 56
5.11 TECHNOLOGY ANALYSIS 56
6 EFFICACY TESTING MARKET, BY SERVICE TYPE 57
6.1 INTRODUCTION 58
TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 58
6.2 DISINFECTANT EFFICACY TESTING 58
TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 60
6.2.1 SURFACE TEST METHOD 60
6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market 60
TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61
TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 61
TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 62
6.2.2 SUSPENSION TEST METHOD 62
6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants 62
TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING 64
TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL 64
TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 64
TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 66
6.3.1 TRADITIONAL TEST METHOD 66
6.3.1.1 Traditional test method segment to dominate AET/PET market 66
TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67
6.3.2 RAPID TEST METHOD 67
6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods 67
TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67
7 EFFICACY TESTING MARKET, BY APPLICATION 68
7.1 INTRODUCTION 69
TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69
7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS 69
7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH 69
TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS 71
7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS 71
TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
7.4 CONSUMER PRODUCT APPLICATIONS 73
7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH 73
TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.5 MEDICAL DEVICE APPLICATIONS 74
7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH 74
TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
8 EFFICACY TESTING MARKET, BY REGION 77
8.1 INTRODUCTION 78
TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 78
8.2 NORTH AMERICA 78
FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT 79
TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 80
TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80
TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80
TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 81
8.2.1 US 81
8.2.1.1 US to dominate North American efficacy testing market during forecast period 81
TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 81
TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 82
TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 82
8.2.2 CANADA 82
8.2.2.1 Government initiatives to drive market growth in Canada 82
TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE,
2020–2027 (USD MILLION) 83
TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83
TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 83
8.3 EUROPE 84
TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 84
TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85
TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85
TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85
8.3.1 GERMANY 86
8.3.1.1 Germany to account for largest share in European market 86
TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 86
TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86
TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86
8.3.2 FRANCE 87
8.3.2.1 High demand for cosmetics in France to drive market growth 87
TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 87
TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 87
TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88

8.3.3 UK 88
8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards 88
TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 88
TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 89
TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89
8.3.4 ITALY 89
8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth 89
TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 90
TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 90
TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90
8.3.5 SPAIN 90
8.3.5.1 Rising R&D expenditure to boost market growth in Spain 90
TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 91
TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 91
TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
8.3.6 REST OF EUROPE 92
TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 92
TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92
TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92
8.4 ASIA PACIFIC 93
FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT 93
TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 94
TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94
TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94
TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
8.4.1 CHINA 95
8.4.1.1 China to dominate Asia Pacific market 95
TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE,
2020–2027 (USD MILLION) 95
TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 96
TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
8.4.2 JAPAN 96
8.4.2.1 Rising R&D investments to drive market growth in Japan 96
TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 96
TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97
TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97
8.4.3 INDIA 97
8.4.3.1 Growing pharmaceutical industry in India to drive market growth 97
TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 98
TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 98
TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
8.4.4 REST OF ASIA PACIFIC 98
TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 99
TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 99
TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
8.5 REST OF THE WORLD 100
TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 100
TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100
TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100
TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 101
8.5.1 LATIN AMERICA 101
8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America 101
TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 101
TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102
8.5.2 MIDDLE EAST AND AFRICA 102
8.5.2.1 UAE has emerged as key market in MEA region 102
TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 102
TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 103
9 COMPETITIVE LANDSCAPE 104
9.1 OVERVIEW 104
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 105
FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019–2022 105
9.3 MARKET SHARE ANALYSIS 106
FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021 106
TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION 106
9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 107
9.5 COMPANY EVALUATION QUADRANT 108
9.5.1 STARS 108
9.5.2 EMERGING LEADERS 108
9.5.3 PERVASIVE PLAYERS 108
9.5.4 PARTICIPANTS 108
9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 110
9.6.1 PROGRESSIVE COMPANIES 110
9.6.2 STARTING BLOCKS 110
9.6.3 RESPONSIVE COMPANIES 110
9.6.4 DYNAMIC COMPANIES 110
9.7 FOOTPRINT ANALYSIS OF COMPANIES 112
9.7.1 SERVICE FOOTPRINT OF COMPANIES 112
TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 112
9.7.2 REGIONAL FOOTPRINT OF COMPANIES 113
TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 113
9.8 COMPETITIVE SCENARIO 114
TABLE 111 PRODUCT LAUNCHES 114
TABLE 112 DEALS 114
TABLE 113 OTHER DEVELOPMENTS 115
10 COMPANY PROFILES 116
10.1 EFFICACY TESTING SERVICE PROVIDERS 116
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 EUROFINS SCIENTIFIC 116
TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 116
FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 117
10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 119
TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 119
FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.:
COMPANY SNAPSHOT (2021) 120

10.1.3 WUXI APPTEC 122
TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW 122
FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021) 123
10.1.4 SGS SA 125
TABLE 117 SGS SA: BUSINESS OVERVIEW 125
10.1.5 INTERTEK GROUP PLC 127
TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW 127
FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 128
10.1.6 MICROCHEM LABORATORY 130
TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW 130
10.1.7 ACCUGEN LABORATORIES, INC. 131
TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW 131
10.1.8 PACIFIC BIOLABS 133
TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW 133
10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES 134
TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW 134
10.1.10 TOXIKON 135
TABLE 123 TOXIKON: BUSINESS OVERVIEW 135
10.1.11 BIOSCIENCE LABORATORIES, INC. 136
TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW 136
10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC) 137
TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW 137
10.1.13 ALMAC GROUP 138
TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW 138
10.1.14 MSL SOLUTION PROVIDERS 139
TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW 139
10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY) 140
TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW 140
10.1.16 ALS LIMITED 141
TABLE 129 ALS LIMITED: BUSINESS OVERVIEW 141
10.1.17 ABBOTT ANALYTICAL 142
TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW 142
10.1.18 BLUTEST LABORATORIES LIMITED 143
TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW 143
10.1.19 LUCIDEON 144
TABLE 132 LUCIDEON: BUSINESS OVERVIEW 144
10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY) 145
TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW 145
10.2 MANUFACTURERS OF DISINFECTANTS 146
10.2.1 PROCTER & GAMBLE 146
TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW 146
FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021) 147
10.2.2 THE CLOROX COMPANY 149
TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW 149
FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021) 149
10.2.3 3M 152
TABLE 136 3M: BUSINESS OVERVIEW 152
FIGURE 31 3M: COMPANY SNAPSHOT (2021) 153
10.2.4 RECKITT BENCKISER GROUP PLC 155
TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW 155
FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021) 156
10.2.5 ECOLAB 158
TABLE 138 ECOLAB: BUSINESS OVERVIEW 158
FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021) 159
10.2.6 STERIS 162
TABLE 139 STERIS: BUSINESS OVERVIEW 162
FIGURE 34 STERIS: COMPANY SNAPSHOT (2021) 163
10.2.7 CANTEL MEDICAL 165
TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW 165
FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021) 166
10.2.8 DIVERSEY HOLDINGS LTD. 168
TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW 168
FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021) 168
10.2.9 CARROLLCLEAN 171
TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW 171
10.2.10 PAUL HARTMANN AG 173
TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW 173
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 175
11.1 DISCUSSION GUIDE 175
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177
11.3 AVAILABLE CUSTOMIZATIONS 179
11.4 RELATED REPORTS 180
11.5 AUTHOR DETAILS 181

ページTOPに戻る

Table of Contents

Summary

The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.
“By method type, the traditional test method accounted for the largest share of the antimicrobial/preservative testing market”
Traditional testing methods generally require microbial assays at multiple test points over extended periods of time. Test durations typically range from a minimum of 28 days to 12 or more weeks. Because standard microbiological techniques similar to those employed in longer-term generic challenge protocols are involved, no special equipment or training is necessary to perform the assay. In fact, this accelerated double challenge (ADC) assay is currently being used in its basic form or in variations at numerous laboratories for a variety of applications.
“The pharmaceutical manufacturing application segment will grow at the highest rate during the forecast period.”
On the basis of application, the efficacy testing market is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications. In 2021, pharmaceutical manufacturing applications were the largest product segment in the market. Growth in this market can be attributed to the increasing R&D manufactures by leading pharmaceutical companies, government support, growth of the pharmaceutical industry, and a growing focus on patient safety.
“The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020–2027).”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, increasing incidence of chronic diseases thereby being responsible for the growth of pharmaceutical products in this region, and the increasing number of pharmaceutical companies that are establishing manufacturing facilities in APAC countries.
“North America: the largest share of the efficacy testing market”
North America accounted for the largest share of the efficacy testing market. Factors such as the presence of a well established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of analytical testing (including efficacy testing) by pharmaceutical and cosmetic companies in the region are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers - 55%
• By Region— North America - 50%, Europe - 20%, APAC – 20%, RoW- 10%

The key players operating in the efficacy testing market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK), BioScience Laboratories, Inc. (US), ALS Limited (Australia), Microchem Laboratory (US), Oxford Biosciences Ltd. (UK), Abbott Analytical (Australia), Helvic Laboratories (a Tentamus Company, UK), Honeyman Group Limited (UK), Danish Technological Institute (DTI, Denmark), and BluTest Laboratories Limited (UK).

Research Coverage:

The report segments the efficacy testing market based on region (Asia Pacific, Europe, North America, and RoW), service type (disinfectant efficacy testing and antimicrobial/preservative efficacy testing), application (pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the efficacy testing market
Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the efficacy testing market and provides them information on key market drivers, challenges, and opportunities.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the efficacy testing market. The report analyzes the market based on the service type, application, and region.
• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service/product launches in the efficacy testing market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of efficacy testing solutions across regions.
• Market Diversification: Exhaustive information about products/ services, untapped regions, recent developments, and investments in the efficacy testing market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the efficacy testing market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他（治療を主目的としない薬物））の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（disinfectant）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

有効性試験の市場：サービスタイプ（抗菌・防腐剤有効性試験、殺菌剤有効性試験）、用途（医薬品、化粧品・パーソナルケア、医療機器、消費者製品）、地域別 - 2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他（治療を主目的としない薬物））の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（disinfectant）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?